Soolantra Cream for 13-Year-Old: Not FDA-Approved for Pediatric Use
Soolantra (ivermectin 1%) cream is not recommended for a 13-year-old patient because safety and effectiveness have not been established in pediatric patients. The FDA drug label explicitly states: "Safety and effectiveness of SOOLANTRA cream in pediatric patients have not been established" 1.
Key Clinical Considerations
FDA Labeling Position
The official prescribing information clearly excludes pediatric use due to lack of clinical trial data in this age group 1. The pivotal clinical trials that led to FDA approval enrolled only subjects aged 18 years and older, with 1,371 adult participants 1, 2. No pediatric safety or efficacy data exists for topical ivermectin cream in rosacea treatment.
Why This Matters for a 13-Year-Old
- No dosing guidance: The pharmacokinetic studies evaluated only adult subjects with severe papulopustular rosacea 1
- Unknown safety profile: While the medication showed low adverse event rates in adults (1.5% treatment-related effects) 3, pediatric skin absorption, metabolism, and tolerance patterns may differ significantly
- Lack of efficacy data: The inflammatory lesion reduction and IGA success rates (38-40% achieving "clear" or "almost clear" status) were demonstrated exclusively in adults 2
Alternative Considerations
If treating rosacea in an adolescent:
- Azelaic acid 15-20%: Has broader age-range data and comparable anti-inflammatory effects 3
- Metronidazole 0.75%: Traditional first-line therapy with established safety profile, though less effective than ivermectin in adult head-to-head trials (75.4% vs 84.9% IGA success) 3
- Encapsulated benzoyl peroxide 5%: FDA-approved for rosacea (2022) with reduced irritation profile 3
Important Caveats
While ivermectin has been studied in pediatric populations for parasitic infections (scabies, onchocerciasis) 4, 5, these are different formulations, different indications, and different dosing regimens than Soolantra cream for rosacea. Recent pediatric ivermectin research focuses on oral formulations for children as young as 3 months for parasitic disease 5, 6, but this does not translate to topical dermatologic use.
The absence of pediatric clinical trials for Soolantra cream means prescribing it to a 13-year-old would be off-label use without supporting safety or efficacy data 1. Given available FDA-approved alternatives with better-established pediatric safety profiles, this represents an unnecessary risk.